Barclays Raises Hims & Hers Target After Novo Deal Clears
Barclays boosts its target on Hims & Hers Health as Novo Nordisk deal removes a key legal overhang, while Progyny see...
Guidance on choosing a retirement age for target date funds, with considerations for work horizon, withdrawals, and risk tolerance.
26,658 articlesBarclays boosts its target on Hims & Hers Health as Novo Nordisk deal removes a key legal overhang, while Progyny see...
A rare bipartisan effort in the U.S. House seeks to shrink the deficit-to-GDP gap to 3% by 2030, with high-profile ba...
If you’re building a resilient income plan, Realty Income stock offers dependable monthly dividends and a carefully c...
The latest inflation data show a notable rise that marks the highest level in years. As investors, we can parse the s...
This week, strategy (formerly microstrategy) stock dropped sharply as Bitcoin volatility clashed with treasury moves....
The Fed just rolled out a new emergency measure that could reshape how we borrow money. This article breaks down what...
A 2x daily leveraged ETF tied to SMCI plunged as its underlying stock posted a modest gain. Experts say daily resets ...
Investors started July with fresh gains as major indices rose and a marquee IPO sparked optimism. Learn what drove th...
A high-profile insider sale at Mineralys raises questions about what it might mean for the biotech's near-term trajec...
Starting July 2026, the federal loan cap for professional programs changes how families fund education. Clark Howard’...
Mortgage rates are moving higher again, but the exact reasons aren’t what many homeowners expect. Learn the hidden fo...
A sharp Friday drop in the Teucrium 2x Long Daily XRP ETF underscores how daily-reset leverage can amplify losses in ...